Your search for major depressive disorder returned 144 results

The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational intranasal formulation of racemic ketamine for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder.

Researchers found evidence for a divergent association between lifetime MDD and the prevalence and severity of symptoms in patients with migraine.

The presence of psychiatric disorders in patients with idiopathic intracranial hypertension is associated with poor treatment outcomes.

The risk for early incident transient ischemic attack and ischemic stroke is significantly higher in young adults with posttraumatic stress disorder.

In a clinical practice guideline, updated recommendations are presented for the evaluation and management of attention-deficit/hyperactivity disorder (ADHD) in children.

Some nutrient supplements may be beneficial as adjunctive treatment for common mental health condition.

The risk factors for tardive dyskinesia in patients taking antipsychotics include age, comorbid diagnoses, and high medication dosages.

Older patients who develop delirium after surgery are more likely to show signs of cognitive dysfunction one month later.

A number of psychiatric and neurodegenerative diseases are associated with abnormal imaging findings, which can help psychiatrists reach a diagnosis.

Migraine with active headache may predict other painful physical symptoms in patients with major depressive disorder.

Cyclic vomiting syndrome (CVS) and benign paroxysmal torticollis (BPT) during infancy are associated with a high risk for developing headache later in life.

Findings suggest VNS to be effective in the treatment of epilepsy and comorbid depression.

Risk of autism spectrum disorder with and without intellectual disability increases with prenatal and infant exposure to several common ambient pesticides.

Investigators analyzed the clinical, psychological, and cognitive factors that affect perceived and cognitive performance fatigability in patients with multiple sclerosis.

Polyneuropathies occurring in multiple sclerosis contribute to neurological disability.

Researchers suggest that improvement in cognitive function should be a goal for major depressive disorder because their data showed little improvement in the cognitive abilities of patients with major depression after treatment with psychological interventions.

Aerobic exercise may be associated with a reduction in the number of migraine days.

The tryptophan-kynurenine-NAD+ (TK) pathway may provide accurate cerebrospinal fluid biomarkers.

Cognitive behavioral therapy may improve a diverse array of depressive symptoms in patients with Parkinson disease.

Investigators predicted the prevalence of depressive symptoms among mothers over the first 10 years after their children were diagnosed with epilepsy and identified trajectories of maternal depressive symptoms over time and baseline characteristics related to each trajectory.

First symptoms and disease type are contributors to delays in multiple sclerosis diagnosis.

Investigators sought to determine how prevalent and severe intractable nausea, vomiting, or hiccups are in patients with AQP4-IgG-positive NMOSD.

Investigators examine the role of physical activity and exercise in the modification of vascular comorbidities and risk factors in individuals with multiple sclerosis.

The treatment is currently being evaluated in a Phase 2 study (ELEVATE) in patients with major depressive disorder who have had an inadequate response to standard antidepressant therapy.

Transcranial magnetic stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain.

Delay or lack of speech, seizures, and walking/balance disorders are some of the symptoms associated with AS.

Investigators aim to facilitate early recognition and consideration for patients with Duchenne muscular dystrophy and internalizing psychiatric symptoms.

Short-term administration of carbapenem antibiotics may be beneficial in the treatment of VPA overdose in patients with no history of seizure disorder.

Mirtazapine is a central alpha-2 antagonist currently FDA-approved for the treatment of major depressive disorder.

Investigators sought to determine the frequency of major depressive disorder in patients in epilepsy clinics.